The hotly anticipated B-Cell Directed Therapies for Autoimmune Diseases Virtual Summit is here to equip you with the expert insight and novel strategies to ensure the therapeutic and commercial success of the next generation of optimized B cell directed candidates.
Join us to shape the drug development fabric of B and plasma cell directed therapies and finally cater to the unmet clinical needs of patients with immune mediated and autoimmune diseases. With 24+ expert speakers – including Cabaletta Bio, Novartis, Pfizer, Biogen, Incyte; 18+ dedicated virtual sessions, and over 3 hours of facilitated video networking – this is your must-attend meeting to understand the interactions which make a combined epigenetic therapy and immunotherapy an attractive approach to circumvent the limitations of immunotherapy alone.
On Tuesday October 13, 2020 at 9:00 am (ends Thursday October 15, 2020 at 4:30 pm)
Industry Pricing: USD 1799.0,
Standard Pricing: USD 2099.0,
Academic Pricing: USD 1499.0
Speakers: Aimee Payne, Professor and Co-Founder of Cabaletta BioUniversity of Pennsylvania, Paul Smith, Senior Director - Pharmacology (Non-Oncology), Incyte Corporation, Amit Choudhury, Principal Scientist: M267 CD38 SIFbody Program Co-Lead, Momenta Pharmaceuticals, Gregory Wu, Associate Professor of Neurology, Washington University in St. Louis, School of Medicine, Jessica Kenison-White, Senior Scientist, AnTolRx, Inc., Claire Langrish, Vice President – Immunology and Biology, Principia Biopharma, Thomas Tedder, Alter Geller Distinguished Professor for Research in Immunology, Duke University School of Medicine, Martin Kaul, Executive Director Translational Medicine, Autoimmunity, Novartis Institutes for Biomedical Research, Michaël Mingueneau, Associate Director, Multiple Sclerosis Research Unit, Biogen, and more!